Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a report published on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Up 8.5 %

Pulmatrix stock opened at $6.10 on Monday. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $8.44. The company has a market capitalization of $22.27 million, a price-to-earnings ratio of -2.31 and a beta of 0.99. The business’s fifty day simple moving average is $2.57 and its two-hundred day simple moving average is $2.21.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.